Bridging therapy was administered to 90% of apheresed patients, with chemotherapy ± radiotherapy used in 53% and targeted ...

Maria Hordinsky, MD, discusses exciting results in alopecia areata, including some discussed at the Winter Clinical Dermatology Conference. In an interview with The American Journal of Managed Care, ...

FDA approval establishes setmelanotide as the first labeled option for acquired hypothalamic obesity, addressing a population ...

Accelerated approval of semaglutide 7.2 mg establishes a higher-dose, once-weekly GLP-1 RA option for long-term weight ...

In this episode, ‘Assessing Clinical and Economic Factors in Treatment Selection and Payer Decision-Making,’ the panelists ...

Across treatment classes, CH associated with increased therapy-related cytopenias, particularly neutropenia, and DNMT3A/TET2 ...

Data analysis reveals a stable, cross-cohort female cancer mortality excess at ages 35-60, contrasting with female advantages in cardiovascular and external-cause mortality. Breast cancer drives the ...

Survival in myeloma is clearly being prolonged,” says Mikhael. “Whereas historically, we saw a greater impact in younger ...

Rural residence is associated with higher advanced-stage (III/IV) diagnosis rates than non-rural cohorts (13.6% vs 12.1%), indicating persistent screening and diagnostic access gaps. Non-Hispanic ...

Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane repair and provide complementary biology for oral combination regimens.

Pulmonary expert Noah Greenspan, DPT, discusses long COVID, early pandemic uncertainty, and how vaccination may help reduce ...

Annual Meeting, James Song, MD, chief medical officer and director of clinical research, Frontier Dermatology, outlines maj ...